Pacira Operating Margin from 2010 to 2024
PCRX Stock | USD 17.55 0.17 0.98% |
Check Pacira BioSciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira BioSciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 79.4 M, Interest Expense of 15.8 M or Selling General Administrative of 63.1 M, as well as many indicators such as Price To Sales Ratio of 2.19, Dividend Yield of 0.0014 or PTB Ratio of 1.7. Pacira financial statements analysis is a perfect complement when working with Pacira BioSciences, Valuation or Volatility modules.
Pacira | Operating Margin |
Latest Pacira BioSciences,'s Operating Margin Growth Pattern
Below is the plot of the Operating Profit Margin of Pacira BioSciences, over the last few years. It is Pacira BioSciences,'s Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira BioSciences,'s overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 0.13 % | 10 Years Trend |
|
Operating Profit Margin |
Timeline |
Pacira Operating Margin Regression Statistics
Arithmetic Mean | (0.47) | |
Coefficient Of Variation | (227.78) | |
Mean Deviation | 0.77 | |
Median | 0.04 | |
Standard Deviation | 1.06 | |
Sample Variance | 1.12 | |
Range | 3.4997 | |
R-Value | 0.76 | |
Mean Square Error | 0.51 | |
R-Squared | 0.58 | |
Significance | 0 | |
Slope | 0.18 | |
Total Sum of Squares | 15.71 |
Pacira Operating Margin History
About Pacira BioSciences, Financial Statements
Pacira BioSciences, investors use historical fundamental indicators, such as Pacira BioSciences,'s Operating Margin, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pacira BioSciences,. Please read more on our technical analysis and fundamental analysis pages.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Pacira Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 697 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.